| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Orchid Cellmark Inc. | 43 |
$65 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Orchid Cellmark | 5 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ORCHID BIOSCIENCES INC (ORCH=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ORCHID BIOSCIENCES INC (ORCH=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ORCHID CELLMARK -- ORCH | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ANIK , ABIO , GNVC , GTCB , LXRX , NBIX , ORCH -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| ORCH: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Consulting Industry Market Research and Competitive Analysis 2009 | 408 |
$299 |
1.48% Nasdaq 
Research Reports
